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In this report, we describe the cloning and characteriz-
ation of Boo, a novel anti-apoptotic member of the Bcl-2
family. The expression of Boo was highly restricted to
the ovary and epididymis implicating it in the control
of ovarian atresia and sperm maturation. Boo contains
the conserved BH1 and BH2 domains, but lacks the
BH3 motif. Like Bcl-2, Boo possesses a hydrophobic
C-terminus and localizes to intracellular membranes.
Boo also has an N-terminal region with strong homo-
logy to the BH4 domain found to be important for
the function of some anti-apoptotic Bcl-2 homologues.
Chromosomal localization analysis assigned Boo to
murine chromosome 9 at band d9. Boo inhibits
apoptosis, homodimerizes or heterodimerizes with
some death-promoting and -suppressing Bcl-2 family
members. More importantly, Boo interacts with Apaf-1
and forms a multimeric protein complex with Apaf-1
and caspase-9. Bak and Bik, two pro-apoptotic homo-
logues disrupt the association of Boo and Apaf-1.
Furthermore, Boo binds to three distinct regions of
Apaf-1. These results demonstrate the evolutionarily
conserved nature of the mechanisms of apoptosis. Like
Ced-9, the mammalian homologues Boo and Bcl-xL
interact with the human counterpart of Ced-4, Apaf-1,
and thereby regulate apoptosis.
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Introduction
Apoptosis, a morphologically distinct form of cell death,
is important for normal development, tissue homeostasis
and defense against pathogenic microorganisms (Raff,
1992; Vaux et al., 1994). Perturbations of apoptosis can
lead to a number of human pathologies such as cancer,
auto-immune disease and neurodegenerative disorders
(Thompson, 1995).
Despite the diversity of stimuli triggering apoptosis and
the wide range of cell types involved, the apoptotic death
machinery is evolutionarily conserved from nematodes to
mammals. Genetic studies in the nematode Caenorhabditis
elegans have identified three core components of the cell-
death machine: ced-3, ced-4 and ced-9 (Hengartner and
Horvitz, 1994c). ced-3 and ced-4 are required for the
execution of the cell-death program and loss-of-function
mutations in either gene result in the survival of all 131
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somatic cells that normally die (Ellis and Horvitz, 1986).
ced-9, in contrast, is a negative regulator of apoptosis
and loss-of-function mutations in ced-9 cause embryonic
lethality as a consequence of ectopic cell death (Hengartner
et al., 1992). ced-3 encodes a cysteine protease with
aspartic acid specificity and is a relative of a family of
caspases (Yuan et al., 1993; Kumar and Harvey, 1995)
that appear to act as the effectors of the cell-death pathway
(Chinnaiyan and Dixit, 1996; Henkart, 1996). These death
proteases exist as zymogens which are activated when the
regulatory prodomain is removed and they assemble into
active heteromeric proteases (Cohen, 1997). The caspase
family now comprises 13 known members which can be
divided into two classes based on the lengths of their
N-terminal prodomains (Humke et al., 1998). Accumulat-
ing evidence suggests that caspases with long domains,
such as caspase-8, and -9, function upstream in the caspase
cascade while caspases with short domains operate at the
downstream end of the cascade (Cohen, 1997; Golstein,
1997). Activation of these distal caspases leads to proteo-
lytic cleavage of a limited number of key protein substrates
and execution of the death program (Cohen, 1997).
The death-repressor gene ced-9, like ced-3, also has
multiple mammalian homologues and its protein product
is structurally and functionally homologous to Bcl-2, the
prototype member of a family of cell-death regulators
(Hengartner and Horvitz, 1994b). First identified for its
role in B-cell malignancies, Bcl-2 when overexpressed
inhibits apoptotic cell death in diverse biological systems
(Reed, 1994). Two functional classes of Bcl-2-related
proteins constitute the family: anti-apoptotic members
(Bcl-2, Bcl-xL, Bcl-w, NR-13, A1 and Mcl-1), which
inhibit cell death, and pro-apoptotic members (Bax, Bak,
Bad, Bik, Bid, Hrk, Bim and Bok/Mtd), which promote
apoptosis (Hsu et al., 1997; Kroemer, 1997; Inohara et al.,
1998a; O’Connor et al., 1998). Sequence alignments of
Bcl-2 family proteins have identified four conserved
domains, designated Bcl-2 homology regions, (BH1 to
BH4) (Chittenden et al., 1995a; Gibson et al., 1996; Zha
et al., 1996). The BH1 and BH2 motifs of the death
antagonists (such as Bcl-2 and Bcl-xL) and the BH3
domain of the death agonists (such as Bax and Bak) are
important for homo- or heterodimerization between family
members (Yin et al., 1994; Chittenden et al., 1995b;
Simonian et al., 1996; Zha et al., 1996). The BH4 domain,
which is restricted to several anti-apoptotic homologues,
appears to be essential for the death-repressing activity
(Huang et al., 1998). An early model proposed that the
balance between pro- and anti-apoptotic Bcl-2 proteins
determines cell fate (Oltvai et al., 1993; Boise et al.,
1995; White, 1996; Kroemer, 1997). Contrary to this
model, suppression or induction of cell death in some
systems is independent of their interactions (Cheng et al.,
1996, 1997; Simonian et al., 1996).
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Fig. 1. Sequence characterization of Boo. (A) Deduced amino acid sequence of Boo. (B) Alignment of Boo amino acid sequence with those of
mouse Bcl-2, Bcl-xL, Bcl-w and chicken NR-13. The numbers on the left indicate the positions of the amino acid in each sequence. The conserved
BH domains (1–4) and the C-terminal hydrophobic region (TM, transmembrane) are indicated. Shading marks identical residues. The DDBJ/EMBL/
GenBank accession number for Boo is AF102501.
Genetic analysis in C.elegans indicates that Ced-9
prevents Ced-4 from activating the nematode caspase
Ced-3 (Shaham and Horvitz, 1996a,b). Consistent with
this, Bcl-2 and Bcl-xL have been shown to function
upstream of some of the caspases in the cell-death pathway
(Armstrong et al., 1996; Chinnaiyan et al., 1996). How-
ever, the precise mechanism by which these death antagon-
ists regulate caspase activation and apoptosis remains
unclear.
Recently, a connection has been established between
members of the Ced-9/Bcl-2 family and caspases. Ced-4
interacts with and promotes the activation of Ced-3,
and this activation is inhibited by Ced-9 through direct
interaction with Ced-4 (Chinnaiyan et al., 1997; Spector
et al., 1997; Wu et al., 1997a,b). Likewise, a similar
mechanism also exists in mammalian cells. Apaf-1, a
mammalian counterpart of Ced-4 (Zou et al., 1997),
simultaneously and independently binds to Bcl-xL and
caspase-9 (Hu et al., 1998; Pan et al., 1998). Bcl-xL
interacts with Apaf-1 and blocks Apaf-1-dependent cas-
pase-9 activation (Hu et al., 1998), further confirming the
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high degree of evolutionary conservation in the cell-death
machinery.
In the present study, we report the identification and
characterization of Boo, for Bcl-2 homologue of ovary, a
novel anti-apoptotic member of the Bcl-2 family. Boo was
exclusively expressed in the ovary and the epididymis.
Boo inhibited apoptosis and interacted with selective pro-
and anti-apoptotic Bcl-2 family proteins. Furthermore,
Boo bound to Apaf-1 at multiple sites implicating it in the
regulation of this central component of the death pathway.
Results
Isolation of Boo, a novel Bcl-2-related gene
In an attempt to identify novel apoptosis-regulatory pro-
teins, we searched the GenBankTM expressed-sequence
tag (EST) database for cDNAs encoding proteins with
homology to chicken neuroretina (NR-13). Several over-
lapping clones were identified as having statistically signi-
ficant homology to NR-13. A clone AA623872 (IMAGE
Consortium Clone ID 1108004) was characterized further
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and analysis of its nucleotide sequence revealed an open
reading frame that encoded a protein of 191 amino acids
with a predicted relative molecular mass of 22 300 Da
(Figure 1A). We designated this gene as Boo. Sequence
analysis revealed that Boo was a novel member of the
Bcl-2 family with conserved BH1 and BH2 domains
(Figure 1B). Several residues conserved in the BH domains
of NR-13, Bcl-2 and Bcl-xL are different in the Boo
sequence. For example, Boo has substituted Ser88 and
Arg144 for Gly and Trp found at the equivalent position
in other anti-apoptotic Bcl-2 family members (Figure 1B).
Hydrophilicity analysis indicated that the protein has a C-
terminal transmembrane region (Figure 1B) which is
expected to mediate intracellular membrane localization
(Kroemer, 1997). Close inspection of its sequence revealed
a stretch of 17 amino acids sharing significant homology
with the BH4 domain known to be important for the anti-
apoptotic function of mammalian Bcl-2 proteins (Figure
1B). However, Boo lacks a recognizable BH3 domain
found in all pro-apoptotic members of the Bcl-2 family.
Boo displays a highly restricted expression in
mouse tissues
To characterize Boo further, its expression in various
mouse adult and embryonic tissues was examined by
Northern blot analysis. Surprisingly, Boo mRNA was
undetectable or at very low levels in heart, brain, spleen,
lung, liver, skeletal muscle, kidney and testis (data not
shown). Moreover, no expression was found during
embryonic development from E7–E17 (data not shown).
Given that all the EST clones were derived from unfertil-
ized, fertilized and 2-cell stage mouse eggs, we reasoned
that the expression of Boo may be restricted to the ovary
and other reproductive organs. Indeed, further analysis of
a mouse RNA master blot, which contains poly(A) RNAs
from different tissues and developmental stages, showed
that Boo mRNA was predominantly expressed in the
ovary and weakly in the epididymis but not in the other
tissues examined (Figure 2).
Boo is a non-nuclear intracellular protein
To assess subcellular localization, we expressed Boo in
293T cells as a fusion protein with an N-terminal Flag
epitope tag. Immuno-staining with anti-Flag antibodies
and visualization by fluorescence microscopy was carried
out 24 h after transfection. Analysis of labeled cells with
an anti-Flag monoclonal antibody revealed that Flag-Boo
displayed a compact, granular and extranuclear staining
pattern, consistent with an association with membranes of
intracellular organelles and the perinuclear region (Figure
3A). The pattern of Boo staining was strikingly similar to
that reported for Ced-9, Bcl-2 and Bcl-xL (Krajewski
et al., 1993; Gonzalez-Garcia et al., 1994; Wu et al.,
1997b), suggesting that Boo, Bcl-2 and Bcl-xL localize to
similar intracellular compartments in mammalian cells.
The specificity of the labeling was confirmed by comparing
the staining pattern with that of cells transfected with a
control Flag-tagged GATA-1 expression plasmid. Staining
of GATA-1 protein with an anti-Flag antibody revealed
the nuclear labeling pattern expected for a transcription
factor (Figure 3B).
Localization was also assayed independently by sub-
cellular fractionation studies. Transfected 293T cells were
169
Fig. 2. Distribution of Boo in mouse tissues. Boo was hybridized to
poly(A) RNA derived from the following mouse tissues: brain (A1),
eye (A2), liver (A3), lung (A4), kidney (A5), heart (B1), skeletal
muscle (B2), smooth muscle (B3), pancreas (C1), thyroid (C2),
thymus (C3), submaxillary gland (C4), spleen (C5), testis (D1), ovary
(D2), prostate (D3), epididymis (D4), uterus (D5), embryo 7 days
(E1), embryo 11 days (E2), embryo 15 days (E3), embryo 17 days
(E4), yeast total RNA (F1), yeast tRNA (F2), E.coli rRNA (F3), E.coli
DNA (F4), poly r(A) (G1), Cot1 DNA (G2), mouse DNA (G3) and
mouse DNA (G4). The same filter was reprobed with β-actin for
calibration.
lysed and fractionated into a nuclear, cytosolic and a
membrane fraction. Boo was found predominantly in the
membrane fraction and some in the low-speed nuclear
pellet (Figure 3C). The transcription factor GATA-1 was
found exclusively in the nuclear pellet (Figure 3D). These
results are consistent with the immunolocalization data and
further establish the similarities in subcellular localization
between Boo and Bcl-2 (O’Connor et al., 1998).
Overexpression of Boo inhibits apoptosis
To assess its role in regulation of apoptosis, the Flag-tagged
Boo expression plasmid was transfected into FL5.12, an
interleukin-3 (IL-3)-dependent prolymphocytic cell line
and Baf-3, an IL-3-dependent bone marrow-derived cell
line. For comparison, cell lines were also transfected
with Flag-Bcl-2 and Flag-Bcl-xL expression plasmids,
respectively. Stable clones expressing comparably high
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Fig. 3. Subcellular localization of Boo in 293T cells. Cells were transiently transfected with expression plasmids encoding Flag-Boo (A) or Flag-
GATA-1 as a control (B). Shown are images after labeling with anti-Flag and secondary fluorescein-conjugated antibody. Samples were prepared at
24 h after transfection. Arrow, perinuclear region; N, nucleus. Subcellular fractionation of lysates from 293T cells expressing Flag-Boo (C) or Flag-
GATA-1 (D). Lysates from equivalent numbers of unfractionated cells (whole) and of subcellular fractions (nuclear, cytoplasmic or membrane), were
resolved by SDS–PAGE and immunoblotted using anti-Flag monoclonal antibody.
levels of Boo, Bcl-2 and Bcl-xL proteins were selected
for further study.
To ascertain whether Boo enhanced or antagonized cell
survival, the transfected cell lines were subjected to various
cytotoxic conditions. Cells transfected with expression
vectors containing only the drug resistance gene served
as controls. As shown in Figure 4, both FL5.12 and Baf-3
cells transfected with the neomycin construct alone died
rapidly upon IL-3 withdrawal. In contrast, when Boo
transfectants were subjected to IL-3 deprivation, they
displayed dramatic resistance to cell death and the kinetics
of their survival were comparable with that of cells
overexpressing either Bcl-2 or Bcl-xL (Figure 4A and B,
left panels). To further compare the anti-apoptotic spectrum
of Boo with its homologues, we also exposed FL5.12
and Baf-3 clones to γ-irradiation and cyclosporin A,
respectively. Anti-apoptotic Bcl-2 family members have
been shown to protect effectively against ionizing radi-
ation-induced cell death as well as the immunosuppressant
cyclosporin A (Huang et al., 1997). Boo effectively
antagonized both γ-irradiation and cyclosporin A-induced
apoptosis (Figure 4A and B, right panels). No significant
difference could be detected in the level of protection
against these two cytotoxic agents conferred by Boo,
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Bcl-2 and Bcl-xL. Collectively, these results clearly place
Boo in the sub-family of Bcl-2-related proteins that inhibit
cell death.
Localization of mouse Boo gene
Fluorescence in situ hybridization analysis using a mouse
Boo genomic probe clearly assigned Boo to mouse chromo-
some 9 at band d9 (Figure 5). Of the 80 metaphases
scored for fluorescent signal using the intron probe, 73
exhibited specific labeling at 9d9.
Boo forms homodimers and heterodimerizes with
other Bcl-2 members
To determine whether Boo could form homodimers, we co-
transfected 293T cells with expression plasmids producing
Flag-Boo and Boo-Myc or a control plasmid. Immuno-
precipitates were prepared using an anti-Flag monoclonal
antibody, and separated by SDS–PAGE. Immuno-
blotting with anti-Myc antibody revealed co-precipitated
Boo-Myc, indicating the presence of Boo homodimers
(Figure 6A). To assess whether Boo interacts with
Bcl-2 and Bcl-xL in mammalian cells, we performed
co-immunoprecipitation in 293T cells. As shown in
Figure 6B, Boo bound strongly to Bcl-xL and weakly to
Boo, a new Bcl-2 homologue
Fig. 4. Effect of Boo, Bcl-2 and Bcl-xL on apoptosis induced by IL-3 deprivation, γ-irradiation or cyclosporin A. (A) FL5.12 cells were either
washed three times and cultured in medium lacking IL-3 (left panel) or irradiated (15 Gy) and cultured in conditioned medium (right panel).
(B) Baf-3 cells were washed three times and cultured in medium lacking IL-3 (left panel) or cultured in non-conditioned medium containing
100 μg/ml cyclosporin A (right panel). Cultures were initiated at 2.5105 cells/ml and cell viability was determined by Trypan blue exclusion.
Results are arithmetic means  SD of at least three experiments and are representative of the results obtained with at least three independent clones.
Bcl-2. Because Boo could inhibit apoptosis induced by
different stimuli, we further tested the ability of Boo to
interact with Bax, Bak, Bad, Bik and Bid, five pro-
apoptotic members of the Bcl-2 family. Associations of
Boo with Bak and Bik were readily detected when these
proteins were co-expressed in vivo (Figure 6C), whereas
Bax, Bad and Bid failed to co-precipitate with Boo. These
results indicate that Boo interacts only with selective anti-
and pro-apoptotic Bcl-2 proteins.
Boo blocks Bak- and Bik-induced apoptosis
In view of the ability of Boo to heterodimerize with Bak
and Bik, we next determined whether Boo could block
the killing activity of Bak and Bik. In MCF7 cells,
overexpression of Bak or Bik induced apoptosis in ~90
and 85% of cells, respectively, but Boo effectively coun-
tered Bak- and Bik-mediated killing in this transient assay
(Figure 7). On the other hand, Boo did not inhibit Bax-
induced cell death (Figure 7). Thus, the anti-apoptotic
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activity of Boo correlated with its ability to heterodimerize
to pro-apoptotic Bcl-2 homologues.
Boo interacts at multiple sites with Apaf-1
Recent reports demonstrate that Bcl-xL can interact with
Apaf-1, the mammalian counterpart of Ced-4 (Hu et al.,
1998; Pan et al., 1998). We speculated that an equivalent
interaction might exist between Boo and Apaf-1. To
test this, 293T cells were transiently co-transfected with
Apaf-1-Myc and Boo-Flag or Flag-A20, a control protein.
Western blot analysis of protein complexes immuno-
precipitated with anti-Flag antibody revealed that Apaf-
1-Myc co-precipitated with Boo-Flag, but not Flag-A20
(Figure 8B). To determine the interaction specificity
between Boo and Apaf-1, the immunoprecipitation was
also performed in reverse using anti-Myc monoclonal
antibody. As shown in Figure 8, Boo-Flag but not Flag-
A20 co-precipitated with Apaf-1-Myc. To define critical
regions in Apaf-1 required for its interaction with Boo,
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Fig. 5. Localization of Boo on mouse chromosome 9. A Boo genomic probe was used to hybridize to normal metaphase chromosomes derived from
mouse embryo fibroblast cells. Hybridization sites on chromosome 9 are indicated by arrows.
Fig. 6. Boo forms homodimers and interacts with selective Bcl-2 family proteins. (A) Homodimerization. 293T cells were transiently transfected
with Flag-Boo and Boo-Myc or a control vector. Cell lysates were prepared and immunoprecipitated as described in Materials and methods with the
indicated antibodies. Lysates and immunoprecipitates were analyzed by Western blotting as shown. (B) Heterodimerization with Bcl-xL and Bcl-2.
293T cells were transfected with epitope-tagged constructs, and lysates and immunoprecipitates were analyzed by Western blotting as indicated.
(C) Boo selectively binds to Bak and Bik. Cells were co-transfected with Boo-Myc plus pro-apoptotic Bcl-2 family members. Analysis of lysates
and immunoprecipitates was performed by Western blotting as indicated. WB, Western blot analysis; IP, immunoprecipitation.
we engineered five deletion mutants of Apaf-1 (Figure
8A). In initial experiments, an N-terminal deletion mutant
(N-Apaf-1; residues 1–601), that lacks the WD-40 repeat
region and a C-terminal deletion mutant (C-Apaf-1;
residues 602–1194), that contains only the WD-40 repeat
domain were assessed for their ability to interact with
Boo in a co-transfection assay. Western blot analysis of
Boo complexes with anti-Myc antibody revealed that both
the N-Apaf-1 and C-Apaf-1 mutants associated with Boo
(Figure 8B). Furthermore, Boo also bound to a truncated
172
form of Apaf-1 [Apaf-1(34)], that comprises the Ced-3
and Ced-4 homologous regions, and the Apaf-1 unique
segment between the Ced-4-like and WD-40 repeat
domains (Figure 8B). However, Apaf-1(3), a deletion
mutant containing the Ced-3-homologous region, failed
to co-precipitate with Boo (Figure 8B). Thus, these results
indicate that Boo binds to at least three distinct domains
in Apaf-1, the Ced-4-homologous region, the WD-40
repeats, and the Apaf-1 unique domain between the Ced-4-
like and WD-40 repeat regions.
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Fig. 7. Boo inhibits apoptosis induced by Bak or Bik. MCF7 cells
were co-transfected with Bak, Bik or Bax together with a
β-galactosidase-expressing reporter construct in the presence of a
4-fold excess of a control vector or Boo. Cells were stained and
examined as described (Duan et al., 1996).
Boo and caspase-9 form a ternary complex with
Apaf-1
Given that Bcl-xL and caspase-9 form a ternary complex
with Apaf-1 (Pan et al., 1998), we investigated whether
an analogous biochemical interaction may also occur with
Boo. To assess this, 293T cells were transiently co-
transfected with Boo-Myc and caspase-9–DN-Flag (DN,
dominant negative). Immunoprecipitation of caspase-9–
DN-Flag coprecipitated Boo-Myc, but not Myc-TRADD,
a control protein (Figure 9A). A recent study has shown
that the Ced-3 homologous domain of Apaf-1 interacts
with caspase-9 but not Bcl-xL (Pan et al., 1998). Similarly,
in the present study, this truncated version of Apaf-1 also
failed to bind to Boo. To determine further whether
the in vivo interaction between caspase-9 and Boo was
mediated by an endogenous Apaf-1-like protein, expres-
sion plasmids producing caspase-9–DN-Flag, Boo-Myc
and Apaf-1(3)-Myc were co-transfected in 293T cells.
Expression of Apaf-1(3)-Myc in excess significantly
attenuated the ability of caspase-9 to coprecipitate Boo
(Figure 9B), suggesting that this deletion mutant of Apaf-
1 competitively blocked the interaction of caspase-9 with
an endogenous Apaf-1-like molecule, thereby disrupting
the association between caspase-9 and Boo. Moreover,
ectopic expression of Boo did not affect the binding of
caspase-9 to Apaf-1 (Figure 9C), further confirming that
Apaf-1 simultaneously interacts with caspase-9 and Boo,
forming a ternary complex in mammalian cells. The ability
of Bak and Bik to heterodimerize with Boo prompted us
to examine whether these two pro-apoptotic members of
the Bcl-2 family may function by affecting the association
of Boo with Apaf-1. Co-expression of hemagglutinin
(HA)-Bak or HA-Bik disrupted the interaction between
Boo and Apaf-1 (Figure 9D), indicating that both death
promoters may exert their killing activity by abrogating




We have identified a novel regulator of apoptosis, Boo,
which is homologous to Bcl-2, the prototype of the Bcl-2
family. When stably expressed, Boo greatly enhances the
survival of cells exposed to growth factor deprivation,
γ-irradiation or an immunosuppressant, cyclosporin A.
This wide spectrum of anti-apoptotic activity is character-
istic of the Bcl-2 family (Reed, 1994; Huang et al., 1997).
Boo is also protective in transient assays and effectively
inhibits Bik and Bak induced apoptosis. We therefore
conclude that Boo, Bcl-2, and Bcl-xL are functional
homologues. Boo clearly falls into the death-repressing
rather than the death-promoting sub-group of the Bcl-2
family.
Among the anti-apoptotic Bcl-2 proteins, Boo is most
similar to chicken NR-13. Alignment analysis reveals
that the Boo protein contains conserved BH1 and BH2
domains, but lacks the BH3 motif found in all the death
agonists. The presence of a C-terminal transmembrane
region is expected to mediate localization of Boo to
intracellular membranes. Immunofluorescence and sub-
cellular localization experiments in 293T cells support
this view.
Notably, Boo has a serine at position 88 and an arginine
at 144. These residues corresponding to G142 in the BH1
and W185 in the BH2 domain of Bcl-2, which are highly
conserved among other anti-apoptotic family proteins (Yin
et al., 1994; Sedlak et al., 1995). Previous studies have
shown that these positions are important for Bcl-2 function
and heterodimerization with Bax (Yin et al., 1994). How-
ever, replacement of the W residue in Bcl-xL had minimal
effect on their survival function (Cheng et al., 1996).
Moreover, substitution of the G residue with an E residue
in Ced-9 resulted in a gain-of-function mutant (Hengartner
and Horvitz, 1994a). These results indicate that the residues
necessary for the pro-survival activity of Bcl-2 are not
identical to those of Ced-9 and Bcl-xL. We mutated these
positions in Boo and found that expression of the mutant
Boo was equally effective at inhibiting Bak and Bik
induced apoptosis (unpublished data). Thus, Boo is more
similar to Ced-9 and Bcl-xL in its ability to incorporate
silent mutations at these positions.
Recent studies have shown that deletion of the BH4
domain rendered Bcl-2 and Bcl-xL inactive (Huang et al.,
1998), indicating that this domain is essential for death-
suppressing function of Bcl-2 and Bcl-xL. Consistent with
this finding, Boo also has a recognizable BH4 domain,
which may contribute to its inhibitory activity.
The nuclear magnetic resonance (NMR) structural ana-
lysis of Bcl-xL has shown that its BH1, BH2 and BH3
domains form an elongated hydrophobic cleft which can
bind the BH3 domains of death-promoting proteins (Sattler
et al., 1997). Since Boo lacks a BH3 motif, it probably
has an interaction-interface distinct from that of Bcl-xL.
In agreement with this hypothesis, Boo shows a selective
heterodimerization profile by interacting with some (Bak
and Bik) but not other (Bax, Bad and Bid) pro-apoptotic
members. Similarly, Bok/Mtd, a pro-apoptotic Bcl-2
homologue, which lacks a BH4 domain and has a less
conserved BH3 domain than other Bcl-2 proteins, interacts
only with selective anti-apoptotic family molecules (Mcl-1,
BHRF1 and Bfl-1) (Hsu et al., 1997; Inohara et al., 1998a).
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Fig. 8. Boo binds to distinct domains in Apaf-1. (A) Schematic drawing of the Apaf-1 constructs used in this study. (B) 293T cells were co-transfected
with Boo-Flag and the indicated Apaf-1 constructs or a control vector. Flag or Myc immunoprecipitates were analyzed for co-precipitating proteins by
immunoblotting with mAb towards Myc, Flag or horseradish peroxidase (HRP)-conjugated anti-Myc. Expression of Boo and the Apaf-1 constructs was
visualized by Western blotting of the lysates with αFlag or αHRP-Myc antibodies. Asterisk indicates a non-specific band. WB, Western blot analysis;
IP, immunoprecipitation.
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Fig. 9. Boo and caspase-9 form a multimeric complex with Apaf-1. (A) Caspase-9 associates with Boo through an endogenous Apaf-1-like molecule.
293T cells were co-transfected with caspase-9–DN-Flag and Boo-Myc, Myc-TRADD or a control vector. Anti-Flag immunoprecipitates were blotted
with anti-Myc. Expression of the transfected gene products was assayed in lysates by Western blotting as indicated. (B) Co-expression of the Ced-3-
homologous region of Apaf-1 disrupts the association of caspase-9 with Boo. 239T cells were co-transfected with caspase-9–DN-Flag and Boo-Myc
in the presence of a control vector or a construct expressing Apaf-1(3)-Myc. Immunoprecipitation and Western blot analysis was performed as in
(A). (C) Boo does not affect the interaction between caspase-9 and Apaf-1. Caspase-9–DN-Flag was co-expressed with Apaf-1(34)-Myc in the
presence of either a control vector or a Boo-Myc construct. Immunoprecipitation was carried out with anti-Flag affinity gel and blotted with anti-
Myc or HRP-conjugated anti-Myc. Expression of the transfected gene products was assayed in lysates by Western blotting as indicated. (D) Bak or
Bik disrupts the interaction between Apaf-1 and Boo. Boo-Flag and Apaf-1-Myc were co-expressed in the presence of either a control vector, HA-
Bak or HA-Bik. Anti-Flag immunoprecipitates were blotted with anti-Myc. Lysates were analyzed for expression of the transfected gene products by
Western blotting with anti-epitope antibodies as shown. WB, Western blot analysis; IP, immunoprecipitation.
Moreover, the anti-apoptotic KS-Bcl-2 protein, which
contains a poorly conserved BH3 domain and lacks a
BH4 region, can bind neither to Bak and Bik nor to Bcl-2
and Bcl-xL (Cheng et al., 1997). These observations
suggest that anti-apoptotic proteins have a variety of
interaction surfaces for Bcl-2 homologues, and that the
binding specificity is determined by multiple domains.
However, only detailed structural information will permit
full understanding of these protein–protein interactions.
Furthermore, restricted heterodimerization between pro-
and anti-survival members of the family may have evolved
to regulate multiple death and survival signals.
Interestingly, Boo can also interact with Bcl-2 and
Bcl-xL. Consistent with this observation, other death
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antagonists such as Bcl-xL, Mcl-1 and BHRF1 have been
shown to interact with Bcl-2 (Farrow and Brown, 1996;
Brown, 1997). However, the precise role of these dimeriz-
ations between pro-survival proteins in regulation of
apoptosis remains unclear.
It has been proposed that the ratio of pro- to anti-
apoptotic members and their dimerization determine death
or survival. For example, Bcl-2 mutants fails to hetero-
dimerize with Bax and no longer can inhibit apoptosis
(Yin et al., 1994). However, this view was challenged by
the identification of Bcl-xL mutants and a viral homologue,
KS-Bcl-2, that do not interact with Bak or Bik but still
inhibit apoptosis (Cheng et al., 1996, 1997). Surprisingly,
a recent study has shown that Bcl-2 and Bcl-xL mutants
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that can not heterodimerize with Bax or Bak still retain
the ability to interact with Bad (Ottilie et al., 1997),
suggesting that it is difficult to draw definite conclusions
from these studies because of the redundancy among Bcl-2
family proteins.
How might Boo function given that it interacts only
with a subset of Bcl-2 death agonist but protects from a
broad range of apoptotic stimuli? The recent discovery
that Apaf-1 can form a ternary complex with caspase-9
and Bcl-xL has raised the possibility that the death-
suppressing members of the Bcl-2 family function by
regulating Apaf-1-like proteins and thereby controlling
activation of procaspases and cell death (Li et al., 1997;
Hu et al., 1998; Pan et al., 1998). In keeping with this
hypothesis, here we have shown that Boo interacts with
Apaf-1. We further demonstrate that Boo associates with
caspase-9. The biochemical linkage between Boo and
caspase-9 could be attenuated by the presence of a deletion
mutant of Apaf-1 that binds caspase-9 but not Boo. This
led to the suggestion that the interaction between Boo and
caspase-9 is mediated by an endogenous Apaf-1 and that
mutant Apaf-1 blocks the recruitment of endogenous
Apaf-1 and thus Boo to caspase-9. The observation that
overexpressed Boo did not compete for the association
between caspase-9 and Apaf-1 provides additional evid-
ence that Apaf-1 simultaneously interacts with caspase-9
and Boo, forming a ternary complex in mammalian cells.
This complex can be disrupted by Bak and Bik. These
results, taken together with the recent evidence that Bax
and Bak can abolish the association of Bcl-xL with Apaf-1
(Pan et al., 1998), indicate that the death-promoting Bcl-2
family homologues may function by binding to death-
repressing members of the Bcl-2 family and displacing
Apaf-1-like molecules, thereby permitting the activation
of procaspases. These data imply that anti-apoptotic Bcl-2
homologues have the dominant function in regulating
apoptosis.
We found that Boo binds to three distinct regions in
Apaf-1. Since Bcl-xL could not inhibit caspase-9 matur-
ation mediated by an N-terminal mutant of Apaf-1 which
contains only the Ced-4-like domain (Hu et al., 1998), it
is conceivable that both the WD-40 repeat region and
the Apaf-1 unique segment act as regulatory elements
controlling the activity of Apaf-1. Binding of Boo to these
two domains could induce a conformational change in
Apaf-1 that would inactivate Apaf-1 and thus inhibit the
processing of caspase-9. We are currently testing these
possibilities.
The tissue distribution of Boo is the most restricted of
any of the Bcl-2 family members. The expression of Boo
in the epipidymis may indicate that it contributes to sperm
maturation. A precedent for a specific role of the Bcl-2
family of proteins in the regulation of the male reproductive
tract is the ROSA41 mouse strain that carries a disrupted
Bclw gene. Although Bclw is expressed widely, its inactiv-
ation leads mainly to reduced size of the testis and
seminal vesicles causing sterility (Ross et al., 1998). Bcl-2
overexpression in spermatogonia and loss of function of
Bax also leads to disruption of spermatogenesis (Knudson
et al., 1995; Furuchi et al., 1996). This implies that several
Bcl-2 homologues with very similar functional properties
are necessary during different stages of sperm maturation
176
and Boo is likely to be important during the epipididy-
mal phase.
Highest expression of Boo is detected in the ovaries.
Cell loss in the ovaries occurs during pre and post-
natal ovarian development (Beaumont and Mandl, 1962).
Apoptotic cell death plays an important role during this
process (Tilly, 1996). In addition, oocytes are particularly
sensitive to chemo- and radiotherapy and such treatments
often lead to sterility (Familiari et al., 1993; Ried and Jaffe,
1994). Therefore, understanding the molecular processes
specific for ovarian apoptosis are of considerable interest.
Boo is not the only anti-apoptotic Bcl-2 homologue
expressed in the ovary. Mcl-1, Bcl-2 and Bcl-x have also
been detected in ovarian tissues (Tilly et al., 1995; Hsu
et al., 1997). Multiple pro- and anti-apoptotic proteins
have been shown to have an effect on oocyte apoptosis.
For example, Bcl-2 knock-out mice contain aberrantly
formed primordial follicles (Ratts et al., 1995). The oocytes
of Bax as well as caspase-2 knock-out mice are remarkably
resistant to doxorubicin-induced apoptosis (Perez et al.,
1997; Bergeron et al., 1998). Therefore, more detailed
studies need to be carried out to understand the interplay
of these molecules in the ovarian context. Targeted gene
disruption of Boo should be part of such an analysis.
Materials and methods
Cloning Boo and expression vectors
The partial nucleotide sequences of cDNAs encoding peptides with
homology to chicken NR-13 were found in EST database of GenBank™
using the TBLASTN program. The nucleotide sequence of EST clones
1108004 (DDBJ/EMBL/GenBank accession No. AA623872) was deter-
mined by dideoxy sequencing. The full-length Boo from EST clone
1108004 was cloned into pcDNA3 (Invitrogen) with a N- or C-terminal
Flag tag, or a C-terminal Myc tag. The full-length Apaf-1 was cloned
into pcDNA3.1(–)/Myc-His B (Invitrogen). The truncated mutants of
Apaf-1, N-Apaf-1, C-Apaf-1, M-Apaf-1, Apaf-1(34), Apaf-1(3) and
Apaf-1(4) were amplified by PCR using the Apaf-1 cDNA as a template
and also cloned into pcDNA3.1(–)/Myc-His B. Bad and Bid were cloned
into pcDNA3 with a N-terminal HA tag. The constructs encoding Flag-
Bcl-2, Flag-Bcl-xL, HA-Bax, HA-Bak, HA-Bik, caspase-9–DN-Flag and
Myc-TRADD have been described previously (Chinnaiyan et al., 1996,
1997; Duan et al., 1996; Duan and Dixit, 1997).
Northern blot analysis
A fragment (nucleotides 1–1008) of the Boo cDNA was radiolabeled by
PCR-labeling method and applied for analysis of mouse adult and
embryo multiple-tissue Northern blots, and mouse RNA master blot
(Clontech) according to the manufacturer’s instructions. The mouse
RNA master blot was also hybridized with a β-actin cDNA probe.
Tissue culture, stable transfection and cell-viability assay
MCF7, a human breast carcinoma cell line was cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum
(FBS), non-essential amino acids, L-glutamine, and penicillin/strepto-
mycin. FL5.12, an IL-3-dependent murine pro-B lymphocyte line and
Baf-3, an IL-3-dependent bone marrow-derived line were cultured in the
same medium supplemented with 10% WEHI-3B-conditioned medium as
a source of IL-3. Dulbecco’s modified Eagle’s medium containing 10%
FBS, non-essential amino acids, L-glutamine and penicillin/streptomycin
was used to maintain the 293T cells.
FL5.12 and Baf-3 cells were transfected using a Gene-pulser (Bio-
Rad) with pcDNA3 plasmid containing Flag-Boo, Flag-Bcl-2 or Flag-
Bcl-xL or a control pcDNA3 plasmid (200 V, 960 μF). Transfectants
were selected by growth in G418 (1 mg/ml). Individual clones were
isolated by limiting dilution of a polyclonal neomycin-resistant population
into 96-well plates and then screened for the expression of the transfected
gene of interest by immunoblotting. Clones expressing comparably high
levels of Flag-Boo, Flag-Bcl-2 and Flag-Bcl-xL were selected for
further study.
Boo, a new Bcl-2 homologue
To test their sensitivity to apoptosis, FL5.12 cells were cultured in
IL-3-free medium, or in IL-3-containing medium after exposure to 15 Gy
of γ-irradiation (provided by a 60Co source at a rate of 215 cGy/min).
Baf-3 cells were cultured in IL-3-free medium, or in IL-3-free medium
supplemented with 100 μg/ml of cyclosporin A (Sigma). Cell viability
was determined by Trypan blue exclusion and counting in a hemocyto-
meter. The percentage of survival cells represents the mean value from




To investigate the subcellular localization of Boo, 293T cells were
transfected with pcDNA3–Flag-Boo, pcDNA–Flag-GATA-1, or empty
vector as described above. Twenty-four hours after transfection, cells
were incubated with anti-Flag antibody for 1 h at 23°C and the labeling
was visualized with fluorescein-conjugated goat anti-mouse IgG. After
washing, the cells were mounted in Vectashield mounting medium (Vector
Laboratories, Inc.) and examined with a Leitz orthoplan fluorescence
microscope. To test for protein–protein interactions in vivo, 293T cells
were transiently transfected with indicated plasmids by calcium phosphate
precipitation.
For subcellular fractionation, lysates were prepared as described
previously (O’Connor et al., 1998). Briefly, 2106 cells were homo-
genized in 1 ml of hypotonic lysis buffer (10 mM Tris–HCl pH 7.4,
0.5 μg/ml Pefabloc, 1 μg/ml each of leupeptin, aprotinin, soybean trypsin
inhibitor and pepstatin, 5 mM NaF and 2 mM Na3VO4) with a Dounce
homogenizer. The lysates were centrifuged at 900 g for 10 min to obtain
the nuclear pellet and the supernatant centrifuged at 130 000 g for 60 min
to obtain the soluble cytosolic and the pelleted membrane fractions.
Protein immunoprecipitation and Western blot analysis with relevant
antibodies were performed as described previously (Duan and Dixit,
1997). Briefly, cells were lysed in 1 ml of lysis buffer (20 mM Tris
pH 8.0, 137 mM NaCI, 10% glycerol, 1% nonident P40, 2 mM EDTA)
24–48 h after transfection and soluble lysates were incubated with anti-
Flag, anti-Myc or anti-HA antibodies and protein G–Sepharose (Sigma)
overnight at 4°C. Immune complexes were centrifuged, washed with
excess cold lysis buffer at least three times, and then boiled in gel-
loading buffer. Eluted proteins were subjected to SDS–PAGE, transferred
to nitrocellulose membranes, and immunoblotted with anti-Flag, -Myc
or -HA antibodies.
Apoptosis assay
These were performed essentially as described previously (Duan et al.,
1996). Briefly, MCF7 cells were plated on a six-well tissue culture plate
(2105 cells/well) and transiently transfected with 0.1 μg of the reporter
plasmid pCMV-β-galactosidase plus 0.25 μg of pcDNA3–HA-Bak or
pcDNA3–HA-Bik in the presence or absence of 1 μg of pcDNA3–Flag-
Boo by the Lipofectamine procedure. The total amount of transfected
plasmid DNA was adjusted to 1.5 μg/well by adding pcDNA3. Trans-
fected cells were detected by staining with 5-bromo-4-chloro-3-indolyl
β-D-galactopyranoside as described previously (Duan et al., 1996). The
percentage of apoptotic cells represents the mean value from three
independent experiments.
Fluorescence in situ hybridization
A mouse Boo genomic probe was labeled with digoxigenin dUTP by
nick translation. Labeled probe was combined with sheared mouse DNA
and hybridized to normal metaphase chromosomes derived from mouse
embryo fibroblast cells in a solution containing 50% formamide, 10%
dextran sulfate and 2  saline-sodium citrate buffer. Specific hybridiza-
tion signals were detected by incubating the hybridized slides in
fluoresceinated anti-digoxigenin antibodies followed by counterstaining
with 4,6-diamidino-2-phenylindole (DAPI).
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Note added in proof
The gene for Boo has been recently described as DIVA (Inohara et
al., 1998b).
